Biosimilar Medicines: Types, Approval and Regulation
Biologic medicines are complex products made using living systems, and biosimilars are highly similar versions of approved biologics. Their approval depends on demonstrating comparability with a reference product, while regulation must protect quality and safety and support broader access to treatment.
Biologics and Biosimilars
Biologics are therapeutic products derived from living organisms or their components. They include vaccines, blood and blood components, gene therapies, tissues and recombinant proteins. Unlike chemically synthesised small-molecule drugs, biologics are large, structurally complex molecules whose properties can be sensitive to manufacturing conditions.
- Production: Many biologics are manufactured using biotechnology, including recombinant DNA methods in living cell lines such as Chinese Hamster Ovary (CHO) cells.
- Examples: Insulin, growth hormones, erythropoietin and monoclonal antibodies are biologics. Monoclonal antibodies are engineered immune proteins designed to target particular cells or proteins.
A biosimilar is highly similar to an already approved biological medicine, called the reference product. It must show no clinically meaningful differences from that product in safety, purity and potency. Because biological systems and manufacturing processes are complex, minor differences in clinically inactive components may occur. Biosimilars are not generic drugs. Generics are copies of chemically synthesised medicines; biosimilars are similar, but not identical, to complex biologics. Pebrilzo, for example, is highly similar to Perjeta, which was authorised in the European Union on March 4, 2013.
Types of Biosimilars
Biosimilars are developed across several biologic classes, with use determined by the product’s approved indications.
- Monoclonal antibodies: Biosimilars of infliximab, rituximab, trastuzumab and pertuzumab are used in areas including cancer, autoimmune disease and inflammatory conditions.
- Insulins: Used in the management of diabetes.
- Growth hormones: Used to treat growth hormone deficiency.
- Erythropoietins: Stimulate red blood cell production, including in patients with chronic kidney disease.
- Filgrastims: Stimulate white blood cell production and are often used in patients receiving chemotherapy.
Pertuzumab is an IgG1 monoclonal antibody produced recombinantly in CHO cells. It binds HER2 at its HER3-binding domain, preventing HER2–HER3 dimer formation and blocking the dimer’s signalling. Trastuzumab binds a different HER2 domain; together, the antibodies prevent HER2 from functioning effectively.
Global Approval and Regulation
Biosimilar approval centres on a comparability exercise: evidence is assessed against the reference product rather than establishing safety and efficacy independently from the beginning.
- Analytical assessment: Compares critical quality attributes, including structure, purity and biological activity.
- Functional assessment: Examines mechanisms of action, binding affinity and potency.
- Non-clinical assessment: Includes pharmacokinetic and pharmacodynamic evaluation in animal models.
- Clinical assessment: Targeted human studies confirm comparability, including safety and efficacy for one or more approved indications. These are generally not full-scale trials.
- Regulatory review: The European Medicines Agency (EMA), the US Food and Drug Administration (FDA), Health Canada, Japan’s PMDA and Australia’s TGA have biosimilar regulatory frameworks. The EMA’s Committee for Medicinal Products for Human Use (CHMP) issues opinions on medicines it reviews.
Approval for one indication may be extrapolated to other indications of the reference product when the scientific evidence justifies it. Interchangeability is a separate designation in some jurisdictions. It may allow pharmacist substitution without prescriber intervention and requires additional rigorous assessment; the rules vary by region. In the United States, the Biologics Price Competition and Innovation Act (BPCIA) of 2009 established a biosimilar approval pathway. Regulatory pathways generally assess the totality of comparability evidence, while requirements and decisions remain jurisdiction-specific.
Biosimilar Regulation in India
India’s framework is administered primarily by the Central Drugs Standard Control Organisation (CDSCO), under the Ministry of Health and Family Welfare.
- Guidelines: The Guidelines on Similar Biologics, first issued in 2012 and revised in 2016, set requirements for manufacturing, quality control, and non-clinical and clinical evaluation.
- Review: The process often involves both CDSCO and the Department of Biotechnology (DBT), reflecting the scientific and regulatory complexity of these products.
- Clinical and post-market requirements: Clinical comparability data are required, with the guidelines generally allowing abbreviated trials focused on pharmacokinetics, pharmacodynamics and immunogenicity. Post-market surveillance is required for a specified period to monitor safety and efficacy.
Access, Quality and Innovation
Biosimilars can expand access to biologic treatment by offering alternatives to expensive originator medicines. Competition may reduce costs for patients, healthcare systems and governments, helping systems treat more patients or redirect resources to other needs.
- Affordable access: Lower-cost alternatives may make treatments available to patients who could not otherwise access originator biologics.
- Quality regulation: Comparability requirements and continuing safety monitoring are important because biologics are complex and their properties can be affected by manufacturing.
- Biopharmaceutical innovation: Biosimilar competition can encourage originator companies to invest in new research and development, while widening treatment options.
Key Prelims Takeaways
- Biologics are complex medicines derived from living organisms or their components.
- Biosimilars must show no clinically meaningful differences from their reference products in safety, purity and potency.
- Biosimilars are similar, not identical, to biologics; they are distinct from generic small-molecule drugs.
- The comparability exercise includes analytical, functional, non-clinical and clinical evidence.
- Extrapolation of indications requires scientific justification; interchangeability is a separate, jurisdiction-specific status.
- India’s Guidelines on Similar Biologics were first issued in 2012 and revised in 2016; CDSCO and DBT are involved in the framework.
Recent Context
On November 18, 2026, the European Commission authorised Biocon’s Pebrilzo, a 420 mg pertuzumab biosimilar, for HER2-positive breast cancer; it is the first biosimilar authorised under the EMA’s tailored clinical approach. The FDA approved it on November 16, 2026. Licensed launches are planned for the EU and UK in Q1 2027 and the US in Q3 2028.